{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000113","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.201348+00:00","generated_at":"2026-06-13T19:18:57.252909+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Centessa shareholders approve all proposals at 2023 annual meeting","bullets":["Re-elected directors Carol Stuckley, Brett Zbar, and Mathias Hukkelhoven with over 99.5% support.","KPMG reappointed as UK statutory auditor and independent registered public accounting firm for FY2023.","Adopted UK statutory annual accounts for FY2022; no dividend recommended by directors.","Advisory vote approved directors' remuneration report for FY2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000113","json":"https://secwatch.observer/filing/0001847903-23-000113.json","markdown":"https://secwatch.observer/filing/0001847903-23-000113.md","text":"https://secwatch.observer/filing/0001847903-23-000113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/0001847903-23-000113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/cnta-20230622.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:18:57.252909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1484d143e8b885fafe8f0b375f2c48a25b48fb7d","claim":"Centessa Pharmaceuticals plc shareholders approved Authorization for Audit Committee to determine auditors' remuneration at the 2023-06-22 meeting.","evidence_excerpt":"To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the financial year ending December 31, 2023. 74,160,344 1,954 32,246 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/0001847903-23-000113-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"207892e42167136f9549131347e2a198eb465364","claim":"Centessa Pharmaceuticals plc shareholders approved Ratification of re-appointment of KPMG LLP (Delaware) as independent registered public accounting firm at the 2023-06-22 meeting.","evidence_excerpt":"To ratify the re-appointment of KPMG LLP, a Delaware limited liability partnership, as the Company’s independent registered public accounting firm, for the financial year ending December 31, 2023. 74,161,945 1,450 31,149 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/0001847903-23-000113-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"889f6a49b6362d918d61d2e47e0063150c15e337","claim":"Centessa Pharmaceuticals plc shareholders approved Receive and adopt UK statutory annual accounts and reports for FY2022; note no dividend recommended at the 2023-06-22 meeting.","evidence_excerpt":"To receive and adopt our U.K. statutory annual accounts and reports for the financial year ended December 31, 2022 and to note that the Company’s directors do not recommend the payment of any dividend for the financial year ended December 31, 2022. 74,160,295 2,220 32,029 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/0001847903-23-000113-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"9d41c91172b229d6cd0556c21940bef0de69cdf6","claim":"Centessa Pharmaceuticals plc shareholders approved Reappointment of directors retiring by rotation at the 2023-06-22 meeting.","evidence_excerpt":"To re-appoint as a director Carol Stuckley, M.B.A., who retires by rotation in accordance with the Company’s articles of association. 73,869,967 243,946 80,631 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/0001847903-23-000113-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"a3961b1dcaf439a77cb0c9106c9747a827205416","claim":"Centessa Pharmaceuticals plc shareholders approved Re-appointment of KPMG LLP (UK) as UK statutory auditors at the 2023-06-22 meeting.","evidence_excerpt":"To re-appoint KPMG LLP, a United Kingdom entity, as UK statutory auditors of the Company, to hold office until the conclusion of the next meeting at which the Company’s annual accounts and reports are laid before the Company. 74,152,822 10,473 31,249 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/0001847903-23-000113-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"},{"claim_id":"fe8d82d8eae6f04a0868eacab202095c74a3aac7","claim":"Centessa Pharmaceuticals plc shareholders approved Advisory approval of UK statutory directors' remuneration report for FY2022 at the 2023-06-22 meeting.","evidence_excerpt":"To receive and approve, on an advisory basis, the Company’s U.K. statutory directors’ remuneration report for the financial year ended December 31, 2022. 73,897,670 264,635 32,239 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000113/0001847903-23-000113-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-22"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}